毕马威：全球制药业2030年前景：从进展到巨变-20页.pdfVIP

Pharma outlook 2030: From evolution to revolution A shift in focus KPMG China Pharma 2030 outlook The pharmaceutical sector is at a crossroads. In a heavily disrupted marketplace, characterized by shifting payer attitudes and patient empowerment, neither incremental adjustments nor steady evolution are likely to halt the decline of the traditional pharmaceutical business model. This paper looks ahead to a 2030 scenario to examine the trends revolutionizing the sector; trends that we expect to have dramatic impacts. We believe revenues will fall well short of forecasts as current projections, as well as business and operating models, do not reflect the turbulence in the marketplace. The continued upheaval will give rise to three distinct pharmaceutical archetypes. Executive teams need to carefully consider what type of company they want to be – and plot the optimal path towards this status. By preparing for this future now, organizations not only reduce the risk of decreasing income, but can also open up new opportunities for growth. Over the coming months, we shall produce a series of thought-provoking articles that will examine more deeply specific topics outlined in this paper, which sets the scene for volatile times ahead. Enjoy the read! Roger van den Heuvel Chris Stirling Partner, Head of Life Sciences Partner Global Strategy Group Global Chair, Life Sciences © 2017 KPMG Advisory (China) Limited, a wholly foreign owned enterprise in China and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved. Pharma 2030: From evolution to revolution 2 Seismic shifts Anyone taking a c